Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Tagrisso (osimertinib) has been recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating adult patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
The recommendation follows positive results from the LAURA Phase III trial, which demonstrated a significant improvement in progression-free survival (PFS).
In the trial, Tagrisso reduced the risk of disease progression or death by 84% compared to placebo (HR 0.16; p
Neurizon Therapeutics reports breakthrough preclinical results for ALS treatment candidate NUZ-001
Cytokinetics and Bayer partner on aficamten for Japanese HCM patients
Nektar Therapeutics announces 2024 ACR conference oral presentation of NKTR-422 preclinical data
GRAIL reports first patient tested with blood-based assay in TROPION-Lung12 Phase 3 study
SK Biopharmaceuticals enters radiopharmaceutical therapy research agreement
Adicet Bio doses first patient in Phase 1 trial of ADI-001 for lupus nephritis
Cybin's CYB003 shows 12-month efficacy in Phase 2 MDD trial
Scancell reports promising SCOPE trial data for SCIB1 in advanced melanoma
AstraZeneca's Tagrisso Recommended for EU approval for unresectable EGFR-mutated lung cancer
Martin Pharmaceuticals announces DREAM study results at 75th Annual Liver Meeting of AASLD
Rona Therapeutics reveals positive outcome from RN0191 phase one clinical trial
Merck's KEYTRUDA plus chemotherapy receives positive EU opinion for first-line MPM treatment
Sanofi seeks FDA approval for Dupixent in chronic spontaneous urticaria